Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond

Regeneron is joining its pharma peers in the venture investing sector, committing up to $500 million over the next five years for its new private financing arm.

The New York pharma unveiled Regeneron Ventures on Monday with Jay Markowitz, M.D., and Michael Aberman, M.D., at the helm, both of whom were previously executives at Regeneron. Markowitz said in a release that the outfit would be “agnostic to therapeutic area, technology and stage of development.” That wide-ranging view includes companies beyond drug development, including “devices, tools and enabling technologies.”